Oral Thrush Market Overview
The Oral Thrush Market is expected to reach USD 6,614.74 Million by 2030 at 5.40% CAGR during the forecast period 2022-2030.
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.
Apart from common symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.
Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the Oral Thrush Market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.
Market development represents the best strategy for the Oral Thrush Market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.
Sources: Mayo Clinic, Healthline Media, MRFR Analysis
Figure 1 oral thrush market by types, 2016 (%)
The oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.
Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.
Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
The Americas accounts for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products in the US drives the oral thrush market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger market for oral hygiene products is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of oral thrush treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. Furthermore, the high influence of media and the rise in the awareness regarding oral hygiene coupled with the high per capita income of the population drive the European oral thrush market.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However, Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market. First comer will take advantage and establish the dominance in the African market, which will be difficult to overcome by any new player due to the smaller market size and market value of the African market for oral thrush.
Key Players in the Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.
Oral thrush market valuation can touch USD 6,614.74 Million by 2030.
Oral thrush market is expected to exhibit a CAGR of5.40% from 2022-2030.
Prevalence of Candida in humid and high-temperature regions and detection in immune-compromised patients, smokers, and vulnerable patients can drive the global oral thrush market.
The Americas can hold a major share of the global oral thrush market till 2023.
Bristol Laboratories, Bayer AG, Teva Pharmaceuticals, Ranbaxy Laboratories Limited, Pfizer Inc., GlaxoSmithKline Plc., Wockhardt Ltd., Glenmark Pharmaceuticals, Stellar Pharma, and others are notable players of the global oral thrush market.